SARC Sarcoma SPORE

SARC肉瘤孢子

• 批准号: 8725487
• 负责人: LAURENCE HOWARD BAKER
• 金额: $ 216.2万
• 依托单位: SARC
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-26 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8725487
• 关键词: Accounting; Automobile Driving; Biological; Biological Markers; Biological Process; Biometry; Cancer Biology; Cancer Center; Cell Line; Cessation of life; Clinical; Clinical Research; Clinical Trials; Collaborations; Complex; Databases; Development; Diagnostic; Discipline; Disease; Distant; Early Diagnosis; Epithelial; Evaluation; Ewings sarcoma; Future; G-Protein-Coupled Receptors; Genetic; Genetic Engineering; Goals; Head and neck structure; Health; Human; Image; Individual; Institution; Intervention; Intramural Research Program; Investigation; Knowledge; Laboratories; Lead; Light; Location; Lung; Malignant Neoplasms; Malignant Peripheral Nerve Sheath Tumor; Measures; Medical Oncology; Mesenchymal Cell Neoplasm; Metastatic Neoplasm to the Lung; Metastatic/Recurrent; Michigan; Molecular; Necrosis; Neoplasm Metastasis; Nonprofit Organizations; Operative Surgical Procedures; Outcome; Paraffin Tissue; Pathology; Patients; Pediatric Oncology; Pharmaceutical Preparations; Phase; Pilot Projects; Positron-Emission Tomography; Prevention; Process; Radiation Oncology; Radiation therapy; Radiosurgery; Recurrence; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Retroperitoneal Space; Secure; Signaling Pathway Gene; Site; Specialist; Surgical Oncology; Surgical margins; Survival Rate; Testing; Therapeutic; Tissue Microarray; Tissues; Toxic effect; Translational Research; Translations; Universities; Validation; Xenograft procedure; base; career; chemotherapy; clinically relevant; cost; experience; improved; in vivo Model; innovation; irradiation; mortality; new therapeutic target; novel; novel therapeutic intervention; osteosarcoma; performance site; pre-clinical; programs; response; sarcoma; scaffold; soft tissue; therapeutic target; treatment strategy; tumor

DESCRIPTION (provided by applicant): This application represents unprecedented cooperation among excellent institutions, major sarcoma dedicated non-profit organizations, and the NCI intramural Program. This SPORE originates from SARC, a non-for-profit consortium that facilitates the conduct of research among national centers of excellence in sarcoma. The main goals of the SARC Sarcoma SPORE are the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and - particularly - advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, MD Anderson Cancer Center, and the NCI intramural program, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) HDACi-based therapeutic strategies for the treatment of genetically complex STS; 2) Identification of therapeutic windows for NFI-related malignant peripheral nerve sheath tumor; 3) Investigation of G-protein coupled receptors as biomarkers of aggressive disease and novel therapeutic targets in Ewing sarcoma; and 4) Development of quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy using advanced approaches in PET and MRl. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning; 2) Tissue and Pathology; 3) Clinical Trials; and 4) Biostatistics. The SPORE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also include a Career Developmental Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects, cores and programs are highly integrated and are poised to take maximum advantage of the SPORE mechanism to achieve translational goals. This SPORE joins state-of-the-art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce translational advances.

描述（由申请人提供）：本申请代表了优秀机构，主要肉瘤专用非营利组织和NCI内部计划之间前所未有的合作。这个SPORE来源于SARC，一个非营利的财团，促进了国家肉瘤卓越中心之间的研究。SARC肉瘤孢子的主要目标是将生物和技术进步转化为预防，诊断，结果预测的改进，特别是肉瘤治疗的进步。SARC肉瘤孢子由来自SARC，哈佛，MD安德森癌症中心和NCI内部计划的多名研究人员主持，但也包括来自斯坦福大学，哥伦比亚大学和密歇根大学的关键个人研究人员。研究人员代表医学和儿科肿瘤学，该项目探索软组织和骨肉瘤。本研究提出了四个主要研究项目：1）以HDACi为基础的治疗策略治疗遗传复杂的STS; 2）确定NFI相关的恶性外周神经鞘瘤的治疗窗口; 3）研究G蛋白偶联受体作为尤文肉瘤侵袭性疾病的生物标志物和新的治疗靶点;和4）使用PET和MRI中的先进方法开发用于评估对肉瘤治疗的治疗反应的定量成像生物标志物。这些项目由4个核心整合和支持：1）管理，评估和规划; 2）组织和病理学; 3）临床试验;和4）生物统计学。SPORE应用程序概述了一个发展研究计划，其中包括一个新项目的选择计划以及14个拟议的发展试点项目。我们还包括一个职业发展计划，概述了在转化或临床肉瘤研究中识别和支持有才华的年轻研究人员的机制。项目、核心和程序高度集成，并准备最大限度地利用SPORE机制来实现转化目标。该SPORE将最先进的研究项目与SARC的多机构协作力量以及领先机构的承诺结合起来，以产生转化进展。